Top Stories
Marketing application for dersimelagon in erythropoietic protoporphyria and X-linked protoporphyria was submitted to the FDA in June.
The Phase I/II anti-CD3 antibody for eye inflammation, which got underway in December, was scrapped after a single enrollee.
OmniAb's platform relies on transgenic animals to generate antibodies with human sequences.
Slate is also raising a $245-million private placement to fund development of its two lead migraine assets through Phase II studies.
Duravyu missed its primary endpoint with the company saying unusual vision losses skewed results against Eylea.
Conference News
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ®$17 million in cash and cash equivalents as of June 30, 2026Expanded LYMPHIR commercial and medical a...
-- $30 million financing enables execution of U.S. commercial strategy for the FemaSeed® fertility portfolio and advancement of the FemBloc® clinical and regulatory program toward U.S. approval --ATLA...
STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics f...
The combined company, Fibrx Therapeutics, will start a Phase II trial of RXC008 in fibrostenotic Crohn’s disease.
- Completed quarter with $26.9 million in cash and restricted cash- Key U.S. patent was awarded, protecting exclusivity of stenoparib when used with the stenoparib-specific DRP® companion diagnostic i...
